Nasdaq GlobeNewswire

Advanced Bifurcation Systems Announces Plan for Human Clinical Trials in New Brunswick, Canada

Del

LOS ANGELES, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems ("ABS" or the "Company"), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced that the Company is planning to undertake human clinical trials in New Brunswick, Canada.  The planning for these clinical trials has been initiated with the participation of Dalhousie University's Medical School (DMNB), Horizon Health Network (HHN) where the New Brunswick Heart Center is located, and the New Brunswick Health Research Foundation (NBHRF). The introduction to these institutions was spearheaded by Opportunities NB.

Dr. Mehran Khorsandi, Chairman and Founder of Advanced Bifurcation Systems stated, "ABS is very excited about commencing clinical trials within the New Brunswick health care system. The high quality of the interventional cardiologists, combined with the excellence of the New Brunswick health care system and the institutions that support it, will provide a great resource  for us when we initiate our clinical trials."

Mr. Charles Laverty, Chief Executive Officer of Advanced Bifurcation Systems commented, "We believe the quality of the data from the clinical trials will mirror the strong reputation of outcomes within the New Brunswick health care system and look forward to working with this outstanding team."

"The NBHRF facilitates and supports the Health Research Enterprise in New Brunswick.  We are pleased to witness the interest and commitment of ABS in medical device innovation as well as recognizing the expertise of the Specialists and health professionals at the NBHC and the HHN Research Services.  The conduct of clinical research and clinical trials in New Brunswick is a great testament to our efforts at building out our health research capacity," says Dr. Bruno Battistini, President, CEO and Scientific Director of the New Brunswick Health Research Foundation.   

"ONB is always looking at how to leverage New Brunswick's strengths to bring new opportunities here that will generate economic growth and skilled jobs for New Brunswickers," said ONB CEO Stephen Lund. "This province has world-class assets in the health-research sector, and it is drawing interest from innovative companies like Advanced Bifurcation Systems (ABS) Inc. We are excited to see what ABS can achieve in New Brunswick."

Upon successful completion of the human clinical trials, ABS intends to establish a manufacturing facility in New Brunswick, to serve ABS's customers globally. ABS has incorporated a Canadian subsidiary, Advanced Bifurcation Systems Canada, Inc. to support this effort.

About Advanced Bifurcation Systems

Advanced Bifurcation Systems ("ABS") is a clinical stage medical device company developing an innovative stenting platform for simple treatment of all bifurcation lesions in coronary angioplasties. ABS has developed a novel technology which overcomes the limitations of current approaches while simplifying the procedure.  The Company's groundbreaking system consists of numerous differentiating features, including a unique modular independently movable dual-catheter system for provisional side-branch stenting as well as full bifurcation stenting with a proprietary crimping technology allowing for partial crimping of the main stent.  For more information, go to www.advancedbifurcation.com.

About OPPORTUNITIES NB

Opportunities NB is a Crown corporation that seeks to attract and support opportunities to grow the economy and create jobs. It provides support services for businesses across the province.

About the New Brunswick Health Research Foundation

The New Brunswick Health Research Foundation (NBHRF) was created in July 2008 with a mandate to co-ordinate, support and promote health research in New Brunswick. Our vision is a healthy and prosperous New Brunswick through excellence in health research and innovation. Our mission is to provide leadership and support to build health research capacity, improve the health of New Brunswickers and advance the knowledge economy.

The NBHRF is an independent organization governed by a board of directors comprised of key stakeholders from the health research community in New Brunswick. Provincial funding is provided by Business New Brunswick. 

Contact:

Advanced Bifurcation Systems
Charles Laverty
Chief Executive Officer
charles_laverty@advancedbifurcation.com
(949)432-4824




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Advanced Bifurcation Systems via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Farmako: Cannabis distributor to become gateway to Europe11.12.2018 10:00Pressemelding

Company is first to apply for a licence in the United Kingdom AAA-Team pushes to become gateway to Europe Company first to apply for distribution licences in UK Support of Canadian LP to obtain EU-GMP Focus on research and development FRANKFURT, Germany, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The Frankfurt-based pharmaceutical company Farmako is a research-based pharmaceutical company that distributes medical cannabis. The company is active in all European markets that have created a legal basis for cannabinoid therapies. It is the first company for medical Cannabis pursue distribution licences in multiple European countries. Fort hat, it will rely on EU-GMP certified suppliers. The German market for medical cannabis is estimated at 19.1 million euros in 2018 and at 200 million Euros by 2019. For 2028, experts expect a market volume for medical cannabis of 7.8 billion euros in Germany, an increase by a factor of 400. The number of patients for cannabinoid therapies in Germany has grown from

Kofax RPA Wins DM Award for Artificial Intelligence / Robotic Process Automation Product of the Year11.12.2018 09:00Pressemelding

Recognised as Finalist in Seven Categories, Kofax Named Leader in New Category Reflecting the Evolution of the Document and Content Management Sector IRVINE, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Kofax ® , a leading supplier of intelligent automation (IA) software to digitally transform end-to-end business processes, today announced Kofax RPA was named “AI / Robotic Process Automation Product of the Year” at the 2018 DM Awards, a prestigious awards program conducted by Document Manager Magazine. “By enabling organisations to easily and cost effectively scale their RPA deployments across the enterprise, we’ve raised the bar with Intelligent Automation – the next generation of RPA. We are pleased that the readers of DM Magazine recognise this and honored to receive this award. It is a testament to our success and leadership in the market,” said Reynolds C. Bish, Chief Executive Officer of Kofax. “As the only vendor with cognitive capture, RPA, process orchestration and analytics in i

Skybox Security Appoints Amrit Williams as Vice President of Products11.12.2018 09:00Pressemelding

Williams to accelerate the delivery of product roadmap as demand for advanced cybersecurity management solutions grows SAN JOSE, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Skybox® Security, a global leader in cybersecurity management solutions, announced today that Amrit Williams has joined the company as vice president of products. Williams brings to the company more than 20 years of product innovation and thought leadership in the cybersecurity space. As the head of product management, he will be responsible for driving the Skybox® Security Suite’s product roadmap, focusing on the continuing evolution of the company’s core security management platform and applications addressing firewall, security policy, vulnerability and threat management. “Amrit has an incredible track record of conceiving, developing and delivering to market dozens of award-winning products in both the consumer and enterprise security arenas,” said Gidi Cohen, CEO for Skybox Security. “He has a keen eye to connect

The Graduate Management Admission Council Selects Three New Business Schools for Membership10.12.2018 16:26Pressemelding

Schools Bring Expertise and Insight in Support of GMAC Mission RESTON, Va., Dec. 10, 2018 (GLOBE NEWSWIRE) -- The Graduate Management Admission Council (GMAC), a global association of leading graduate business schools, welcomes three new members. The addition of ESCP Europe, WHU – Otto Beisheim School of Management, and Xavier University Bhubaneswar brings GMAC’s total membership to 225. Select business schools are invited to apply for GMAC membership by its Board of Directors. Each school goes through a comprehensive application process that addresses the sustained commitments to supporting GMAC’s mission: providing the tools and information necessary for schools and talent to discover and evaluate each other. “GMAC continues to strengthen our membership of graduate business schools that are not only working to address the changing needs of students, but also understanding the landscape and what can be done to better prepare students for their careers,” said Sangeet Chowfla, president

Doc re. GE Files Form 8-K10.12.2018 16:08Pressemelding

FAIRFIELD, Conn., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Company General Electric Company ISIN US3696041033 Symbol London: GEC | Paris: GNE Headline Doc re: GE files Form 8-K December 10, 2018 On December 10, 2018, General Electric Company (the "Company") filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC"), which has been submitted to RNS. It is also available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.ge.com/investor-relations/events-reports. http://www.rns-pdf.londonstockexchange.com/rns/0008K_1-2018-12-10.pdf CONTACT: GE Jennifer Erickson +001 646 682 5620 jennifer.erickson@ge.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visi

Robex Resources Inc.: Drilling Results Confirming and Extending Gold Mineralization at Nampala10.12.2018 15:28Pressemelding

QUÉBEC CITY, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Robex Resources Inc. (« Robex » and/or « the Company ») (TSXV : RBX / FWB : RB4) is pleased to provide drilling results from the ongoing drill definition and exploration program at its 100% owned Nampala gold project located in the Sikasso administrative region of the Republic of Mali. The 20,000 meters drill program commenced in September 2018. The program is currently focused on infill drilling within the Nampala open pit and resource area and on exploration drilling on the adjacent Mininko exploration permit. The Company is reporting assay results from 57 drill holes (totaling 5,392 metres): 13 diamond drill holes (totaling 1,272 meters) and 44 RC holes (totaling 4,120 meters). The program is still ongoing and other results will be reported once the results are received, validated and compiled. In this release, significant assay results from 43 intercepts in 23 drill holes are reported herein are provided in Table 1 below and include th

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom